The Correlation between GPX-1 Serum and Hearing Threshold of SLE Patient Post Prednison Therapy

Introduction:Systemic Lupus Erythematous (SLE) is a disease characterized by the involvement of antibodies in the immune system-mediated inflammation, including the auditory system. One of the things that causes hearing loss in SLE is the occurrence of vasculitis and the process of oxidative stress which results in decreasing the activity of Glutathione Peroxidase (GPx) which is one of the important antioxidants in the human body against ROS. Provision of Prednisone therapy in SLE patients with hearing loss will improve hearing. It is expected that there will be an increase in GPx-1 levels along with hearing improvement in SLE patients with hearing loss after receiving prednisone.

Objective:To determine the correlation of hearing threshold with changes of serum GPx-1 levels in systemic lupus erythematosus patients who receiving prednisone therapy.

Method:A comparative analytic study conducted with pre-post design which analyzed the correlation between elevated serum GPx-1 levels and hearing threshold of SLE patients receiving prednisone therapy.

Results:This study found significant changes in GPx-1 levels after SLE patients with hearing loss received prednisone therapy. Comparison of serum GPx-1 levels of SLE patients who experience sensorineural hearing loss before and after prednisone therapy. The statistical test used is the Wilcoxon test and significant if p value <0.05. Comparative test of GPx-1 levels showed a significant number (p <0.001) with increase difference about 3.69U/g Hb. There is significant correlation between the increased serum GPx-1 levels with a decreased hearing threshold shown at high-frequency frequencies at 10,000 Hz and 14,000 Hz (p <0.05).

Conclusion:There is a correlation between improved hearing threshold in increased serum GPx-1 levels in patients receiving prednisone therapy.